Post-traumatic stress disorder and quality of life alterations in survivors of immune-mediated thrombotic thrombocytopenic purpura and atypical hemolytic and uremic syndrome.

[1]  L. Davis,et al.  The Economic Burden of Posttraumatic Stress Disorder in the United States From a Societal Perspective. , 2022, The Journal of clinical psychiatry.

[2]  R. Shaw,et al.  Mind and matter: The neurological complications of thrombotic thrombocytopenic purpura , 2022, British journal of haematology.

[3]  F. Barbier,et al.  Association of COVID-19 Acute Respiratory Distress Syndrome With Symptoms of Posttraumatic Stress Disorder in Family Members After ICU Discharge. , 2022, JAMA.

[4]  N. Freemantle,et al.  Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data , 2021, Clinical nephrology.

[5]  L. Yanek,et al.  Major adverse cardiovascular events in survivors of immune‐mediated thrombotic thrombocytopenic purpura , 2021, American journal of hematology.

[6]  É. Azoulay,et al.  Pattern of Brain Injury in Patients With Thrombotic Thrombocytopenic Purpura in the Precaplacizumab Era , 2021, Critical care medicine.

[7]  S. Wilkins,et al.  Post-traumatic stress disorder and its association with stroke and stroke risk factors: A literature review , 2021, Neurobiology of Stress.

[8]  C. Kröger,et al.  How expensive are post-traumatic stress disorders? Estimating incremental health care and economic costs on anonymised claims data , 2020, The European Journal of Health Economics.

[9]  N. Welton,et al.  Cost-effectiveness of psychological treatments for post-traumatic stress disorder in adults , 2020, PloS one.

[10]  S. Riva,et al.  Long-term neuropsychological sequelae, emotional wellbeing and quality of life in patients with acquired thrombotic thrombocytopenic purpura , 2019, Haematologica.

[11]  J. George.  TTP: long-term outcomes following recovery. , 2018, Hematology. American Society of Hematology. Education Program.

[12]  J. Voorberg,et al.  Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers , 2018, Haematologica.

[13]  A. Mukherjee,et al.  Evaluation of health-related quality of life in hemolytic uraemic syndrome patients treated with eculizumab: a systematic evaluation on basis of EMPRO , 2018, Renal failure.

[14]  R. Gooding,et al.  Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. , 2017, Blood.

[15]  P. Coppo,et al.  Thrombotic thrombocytopenic purpura. , 2017, Blood.

[16]  B. Lämmle,et al.  Depression and cognitive deficits as long‐term consequences of thrombotic thrombocytopenic purpura , 2017, Transfusion.

[17]  K. McCrae,et al.  Post-traumatic stress disorder and depression in survivors of thrombotic thrombocytopenic purpura. , 2017, Thrombosis research.

[18]  Arthur V. Iansavichus,et al.  Long‐term outcomes of thrombotic microangiopathy treated with plasma exchange: A systematic review , 2016, American journal of hematology.

[19]  J. George,et al.  Syndromes of thrombotic microangiopathy. , 2014, The New England journal of medicine.

[20]  N. Talley,et al.  Predictors of Response Rates to a Long Term Follow-Up Mail out Survey , 2013, PloS one.

[21]  S. Vesely,et al.  Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. , 2013, Blood.

[22]  G. Remuzzi,et al.  Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. , 2013, The New England journal of medicine.

[23]  I. Scharrer,et al.  Long term outcome and sequelae in patients after acute thrombotic thrombocytopenic purpura episodes , 2013, Hämostaseologie.

[24]  F. Fabris,et al.  Presence of anti‐ADAMTS13 antibodies in obesity , 2012, European journal of clinical investigation.

[25]  C. Nemeroff,et al.  PAGES_ 12_AG_1004_BA.qxd:DCNS#50 , 2011 .

[26]  P. Maruff,et al.  Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura , 2011, American journal of hematology.

[27]  É. Azoulay,et al.  Health-related quality of life: an outcome variable in critical care survivors. , 2008, Chest.

[28]  J. George.  ADAMTS13, thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome. , 2005, Current hematology reports.

[29]  M. Creamer,et al.  Psychometric properties of the Impact of Event Scale - Revised. , 2003, Behaviour research and therapy.

[30]  R. Snaith,et al.  The Hospital Anxiety And Depression Scale , 2003, Health and quality of life outcomes.

[31]  G. Vaiva,et al.  [Prevalence of trauma-related disorders in the French WHO study: Santé mentale en population générale (SMPG)]. , 2008, L'Encephale.

[32]  S. Vesely,et al.  A support group for patients who have recovered from thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome (TTP‐HUS): The six‐year experience of the Oklahoma TTP‐HUS Study Group , 2003, Journal of clinical apheresis.

[33]  R. Rosser.  Post-traumatic stress disorder. , 1994, The Practitioner.